• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 8, 2014

View Archived Issues

Cerexa gets a split decision in AIDAC meeting on ceftazidime-avibactam

Call it a draw between Cerexa Inc. and the FDA. On the second of a two-day meeting of the Anti-Infective Drugs Advisory Committee (AIDAC), representatives from the Actavis plc subsidiary saw combination antibacterial candidate ceftazidime-avibactam (CAZ/AVI) heartily endorsed to treat two types of serious infections caused by resistant gram-negative pathogens. Read More

FDA approves Incyte's Jakafi for uncontrolled PV

Incyte Corp. has become the first company to win FDA approval for a treatment targeting uncontrolled cases of the rare chronic bone marrow cancer polycythemia vera (PV), which sometimes advances to myelofibrosis. Read More

Hurt locker: Post-phase II pain drug study, Trevena to bank offering of $45M

With positive top-line phase IIa/b results disclosed last month and another phase II trial under way with its pain candidate, TRV130, Trevena Inc. priced a public offering for gross proceeds of about $45 million, selling about 11 million shares at $4 each in a deal expected to close Wednesday. Read More

Antibody mix protects against lethal hantavirus

Human antibodies produced by transchromosomal cows protected hamsters from hantavirus pulmonary syndrome, suggesting that passive vaccination could be a useful strategy against hantavirus. Read More

China's GIBH working with Euclises on COX-2 inhibitor portfolio

HONG KONG – China's government-founded Guangzhou Institutes of Biomedicine and Health (GIBH) has partnered with a U.S. biotech company to co-develop its cancer candidate. Read More

Canbridge takes it to next level with $10M series A from local VC backers

SHANGHAI – Canbridge Life Sciences Inc., a Beijing-based biopharma company started in 2012 with angel and private capital, has received $10 million in a series A investment from leading local health care venture capital funds Qiming Ventures and TF Capital. Read More

Financings

ANI Pharmaceuticals Inc., of Baudette, Minn., said it priced an underwritten public offering of $125 million aggregate principal amount of its 3 percent convertible senior notes due 2019. Read More

Other news to note

Juno Therapeutics Inc., of Seattle, signed an agreement to obtain a license from Opus Bio Inc., of Greenwich, Conn., for a CAR-T cell product candidate targeting CD22, a protein expressed on most B-cell leukemias and lymphomas. Read More

Stock movers

Read More

Pharma: Other news to note

Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said the FDA granted breakthrough therapy designation to oral proteasome inhibitor ixazomib (MLN9708) for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis. Read More

In the clinic

strong>Cellular Biomedicine Group Inc., of Palo Alto, Calif., released 48-week follow-up data analysis of its phase I/IIa trial of Rejoin human adipose-derived mesenchymal progenitor cell (haMPC) regenerative therapy for knee osteoarthritis. Read More

Pharma: In the clinic

Glaxosmithkline plc, of London, presented data at the British Thoracic Society meeting in London, from a systematic analysis of 25 randomized control studies, including a meta-analysis of three key efficacy outcomes, which explored the potential impact of the particle size of different inhaled corticosteroid-containing asthma medicines, including Seretide/Advair (salmeterol/fluticasone proprionate) on patient outcomes. Read More

Bench Press: BioWorld looks at translational medicine

The problem of cancer drug resistance gets the most attention for targeted agents. But tumors can also develop resistance to chemotherapy, with successive rounds of treatment leading to less and less of a response. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe